BBIO Key Statistics, Chart & Performance
The current stock price of BBIO is 68.11 USD. In the past month the price increased by 25.53%. In the past year, price increased by 190.82%.
BBIO Latest News, Press Relases and Analysis
BBIO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 25 | 417.40B | ||
| AMGN | AMGEN INC | 15.43 | 181.72B | ||
| GILD | GILEAD SCIENCES INC | 15.46 | 157.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.58 | 109.42B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.79 | 80.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 855.65 | 57.20B | ||
| INSM | INSMED INC | N/A | 42.01B | ||
| NTRA | NATERA INC | N/A | 31.65B | ||
| BIIB | BIOGEN INC | 10.47 | 25.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.99 | 21.48B | ||
| INCY | INCYTE CORP | 15.9 | 19.93B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.10B |
Related stock screener links
About BBIO
Company Profile
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. The company is headquartered in Palo Alto, California and currently employs 725 full-time employees. The company went IPO on 2019-06-27. The company discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. The company also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.
Company Info
BRIDGEBIO PHARMA INC
3160 Porter Dr., Suite 250
Palo Alto CALIFORNIA 94301 US
CEO: Neil Kumar
Employees: 725
Phone: 16503919740
BRIDGEBIO PHARMA INC / BBIO FAQ
What does BBIO do?
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. The company is headquartered in Palo Alto, California and currently employs 725 full-time employees. The company went IPO on 2019-06-27. The company discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. The company also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.
What is the stock price of BRIDGEBIO PHARMA INC today?
The current stock price of BBIO is 68.11 USD. The price increased by 5.4% in the last trading session.
What is the dividend status of BRIDGEBIO PHARMA INC?
BBIO does not pay a dividend.
What is the ChartMill technical and fundamental rating of BBIO stock?
BBIO has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the expected growth for BBIO stock?
The Revenue of BRIDGEBIO PHARMA INC (BBIO) is expected to grow by 121.3% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the next earnings date for BBIO stock?
BRIDGEBIO PHARMA INC (BBIO) will report earnings on 2026-02-18, after the market close.
Who owns BRIDGEBIO PHARMA INC?
You can find the ownership structure of BRIDGEBIO PHARMA INC (BBIO) on the Ownership tab.
BBIO Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to BBIO. When comparing the yearly performance of all stocks, BBIO is one of the better performing stocks in the market, outperforming 97.84% of all stocks.
BBIO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BBIO. BBIO has a bad profitability rating. Also its financial health evaluation is rather negative.
BBIO Financial Highlights
Over the last trailing twelve months BBIO reported a non-GAAP Earnings per Share(EPS) of -4.18. The EPS decreased by -57.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -79.85% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BBIO Forecast & Estimates
25 analysts have analysed BBIO and the average price target is 82.9 USD. This implies a price increase of 21.71% is expected in the next year compared to the current price of 68.11.
For the next year, analysts expect an EPS growth of -15.03% and a revenue growth 121.3% for BBIO